Results for tag: "Vimizim"

Vimizim is a drug used to treat endocrine and metabolic disorders. It is a recombinant enzyme replacement therapy (ERT) that helps to replace the deficient enzyme in patients with Morquio A Syndrome, a rare genetic disorder. Vimizim is administered intravenously and helps to improve the patient's physical abilities, such as walking, running, and climbing stairs. It also helps to reduce the frequency of skeletal complications associated with the disorder. Vimizim is the only ERT approved by the US Food and Drug Administration (FDA) for the treatment of Morquio A Syndrome. The Vimizim market is composed of a number of companies that specialize in the development and manufacture of ERT drugs. These companies include BioMarin Pharmaceuticals, Shire, and Ultragenyx Pharmaceuticals. They are dedicated to providing innovative treatments for rare diseases and have developed a range of ERT drugs for the treatment of endocrine and metabolic disorders. Show Less Read more